Ramona Plant
GlaxoSmithKline
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ramona Plant.
Molecular Cancer Therapeutics | 2009
Mary Ann Hardwicke; Catherine A. Oleykowski; Ramona Plant; Jamin Wang; Qiaoyin Liao; Katherine G. Moss; Ken A. Newlander; Jerry L. Adams; Dashyant Dhanak; Jingsong Yang; Zhihong Lai; David Sutton; Denis R. Patrick
The protein kinases, Aurora A, B, and C have critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. GSK1070916, is a novel ATP competitive inhibitor that is highly potent and selective for Aurora B/C kinases. Human tumor cells treated with GSK1070916 show dose-dependent inhibition of phosphorylation on serine 10 of Histone H3, a substrate specific for Aurora B kinase. Moreover, GSK1070916 inhibits the proliferation of tumor cells with EC50 values of <10 nmol/L in over 100 cell lines spanning a broad range of tumor types. Although GSK1070916 has potent activity against proliferating cells, a dramatic shift in potency is observed in primary, nondividing, normal human vein endothelial cells, consistent with the proposed mechanism. We further determined that treated cells do not arrest in mitosis but instead fail to divide and become polyploid, ultimately leading to apoptosis. GSK1070916 shows dose-dependent inhibition of phosphorylation of an Aurora B–specific substrate in mice and consistent with its broad cellular activity, has antitumor effects in 10 human tumor xenograft models including breast, colon, lung, and two leukemia models. These results show that GSK1070916 is a potent Aurora B/C kinase inhibitor that has the potential for antitumor activity in a wide range of human cancers. [Mol Cancer Ther 2009;8(7):1808–17]
Journal of Medicinal Chemistry | 2010
Nicholas D. Adams; Jerry L. Adams; Joelle L. Burgess; Amita M. Chaudhari; Robert A. Copeland; Carla A. Donatelli; David H. Drewry; Kelly E. Fisher; Toshihiro Hamajima; Mary Ann Hardwicke; William F. Huffman; Kristin K. Koretke-Brown; Zhihong V. Lai; Octerloney B. McDonald; Hiroko Nakamura; Ken A. Newlander; Catherine A. Oleykowski; Cynthia A. Parrish; Denis R. Patrick; Ramona Plant; Martha A. Sarpong; Kosuke Sasaki; Stanley J. Schmidt; Domingos J. Silva; David Sutton; Jun Tang; Christine Thompson; Peter J. Tummino; Jamin C. Wang; Hong Xiang
The Aurora kinases play critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. Selective inhibitors may provide a new therapy for the treatment of tumors with Aurora kinase amplification. Herein we describe our lead optimization efforts within a 7-azaindole-based series culminating in the identification of GSK1070916 (17k). Key to the advancement of the series was the introduction of a 2-aryl group containing a basic amine onto the azaindole leading to significantly improved cellular activity. Compound 17k is a potent and selective ATP-competitive inhibitor of Aurora B and C with K(i)* values of 0.38 +/- 0.29 and 1.5 +/- 0.4 nM, respectively, and is >250-fold selective over Aurora A. Biochemical characterization revealed that compound 17k has an extremely slow dissociation half-life from Aurora B (>480 min), distinguishing it from clinical compounds 1 and 2. In vitro treatment of A549 human lung cancer cells with compound 17k results in a potent antiproliferative effect (EC(50) = 7 nM). Intraperitoneal administration of 17k in mice bearing human tumor xenografts leads to inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60). Compound 17k is being progressed to human clinical trials.
Bioorganic & Medicinal Chemistry Letters | 2012
Hong Lin; Karl F. Erhard; Mary Ann Hardwicke; Juan I. Luengo; James F. Mack; Jeanelle McSurdy-Freed; Ramona Plant; Kaushik Raha; Cynthia M. Rominger; Robert M. Sanchez; Michael D. Schaber; Mark J. Schulz; Michael D. Spengler; Rosanna Tedesco; Ren Xie; Jin J. Zeng; Ralph A. Rivero
A series of PI3K-beta selective inhibitors, imidazo[1,2-a]-pyrimidin-5(1H)-ones, has been rationally designed based on the docking model of the more potent R enantiomer of TGX-221, identified by a chiral separation, in a PI3K-beta homology model. Synthesis and SAR of this novel chemotype are described. Several compounds in the series demonstrated potent growth inhibition in a PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage independent conditions.
Bioorganic & Medicinal Chemistry Letters | 2012
Robert M. Sanchez; Karl F. Erhard; Mary Ann Hardwicke; Hong Lin; Jeanelle McSurdy-Freed; Ramona Plant; Kaushik Raha; Cynthia M. Rominger; Michael D. Schaber; Michael D. Spengler; Michael L. Moore; Hongyi Yu; Juan I. Luengo; Rosanna Tedesco; Ralph A. Rivero
A series of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones with excellent enzyme inhibition, improved isoform selectivity, and excellent inhibition of downstream phosphorylation of AKT has been identified. Several compounds in the series demonstrated potent (∼ 0.100 μM IC(50)) growth inhibition in a PTEN deficient cancer cell line.
Nature Chemical Biology | 2014
Mary Ann Hardwicke; Alan R. Rendina; Shawn P. Williams; Michael L. Moore; Liping Wang; Julie A Krueger; Ramona Plant; Rachel Totoritis; Guofeng Zhang; Jacques Briand; William Burkhart; Kristin K. Brown; Cynthia A. Parrish
Human fatty acid synthase (hFAS) is a complex, multifunctional enzyme that is solely responsible for the de novo synthesis of long chain fatty acids. hFAS is highly expressed in a number of cancers, with low expression observed in most normal tissues. Although normal tissues tend to obtain fatty acids from the diet, tumor tissues rely on de novo fatty acid synthesis, making hFAS an attractive metabolic target for the treatment of cancer. We describe here the identification of GSK2194069, a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS; the characterization of its enzymatic and cellular mechanism of action; and its inhibition of human tumor cell growth. We also present the design of a new protein construct suitable for crystallography, which resulted in what is to our knowledge the first co-crystal structure of the human KR domain and includes a bound inhibitor.
ACS Medicinal Chemistry Letters | 2012
Hong Lin; Mark J. Schulz; Ren Xie; Jin Zeng; Juan I. Luengo; Michael D. Squire; Rosanna Tedesco; Junya Qu; Karl F. Erhard; James F. Mack; Kaushik Raha; Ramona Plant; Cynthia M. Rominger; Jennifer L. Ariazi; Christian S. Sherk; Michael D. Schaber; Jeanelle McSurdy-Freed; Michael D. Spengler; Charles B. Davis; Mary Ann Hardwicke; Ralph A. Rivero
A novel thiazolopyrimidinone series of PI3K-beta selective inhibitors has been identified. This chemotype has provided an excellent tool compound, 18, that showed potent growth inhibition in the PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage-independent conditions, and it also demonstrated pharmacodynamic effects and efficacy in a PTEN-deficient prostate cancer PC-3 xenograft mouse model.
Bioorganic & Medicinal Chemistry Letters | 2010
Jesus R. Medina; Seth W. Grant; Jeffrey M. Axten; William Henry Miller; Carla A. Donatelli; Mary Ann Hardwicke; Catherine A. Oleykowski; Qiaoyin Liao; Ramona Plant; Hong Xiang
Novel Aurora inhibitors were identified truncating clinical candidate GSK1070916. Many of these truncated compounds retained potent activity against Aurora B with good antiproliferative activity. Mechanistic studies suggested that these compounds, depending on the substitution pattern, may or may not exert their antiproliferative effects via inhibition of Aurora B. The SAR results from this investigation will be presented with an emphasis on the impact structural changes have on the cellular phenotype.
ACS Medicinal Chemistry Letters | 2013
Hongyi Yu; Michael L. Moore; Karl F. Erhard; Mary Ann Hardwicke; Hong Lin; Juan I. Luengo; Jeanelle McSurdy-Freed; Ramona Plant; Junya Qu; Kaushik Raha; Cynthia M. Rominger; Michael D. Schaber; Michael D. Spengler; Ralph A. Rivero
A series of novel [3a,4]dihydropyrazolo[1,5a]pyrimidines were identified, which were highly potent and selective inhibitors of PI3Kβ. The template afforded the opportunity to develop novel SAR for both the hinge-binding (R3) and back-pocket (R4) substitutents. While cellular potency was relatively modest due to high protein binding, the series displayed low clearance in rat, mouse, and monkey.
Journal of Translational Medicine | 2011
Christopher Moy; Catherine A. Oleykowski; Ramona Plant; Joel Greshock; Junping Jing; Kurtis E. Bachman; Mary Ann Hardwicke; Richard Wooster; Yan Degenhardt
BackgroundAurora kinases play critical roles in mitosis and are being evaluated as therapeutic targets in cancer. GSK1070916 is a potent, selective, ATP competitive inhibitor of Aurora kinase B and C. Translation of predictive biomarkers to the clinic can benefit patients by identifying the tumors that are more likely to respond to therapies, especially novel inhibitors such as GSK1070916.Methods59 Hematological cancer-derived cell lines were used as models for response where in vitro sensitivity to GSK1070916 was based on both time and degree of cell death. The response data was analyzed along with karyotype, transcriptomics and somatic mutation profiles to determine predictors of response.Results20 cell lines were sensitive and 39 were resistant to treatment with GSK1070916. High chromosome number was more prevalent in resistant cell lines (p-value = 0.0098, Fisher Exact Test). Greater resistance was also found in cell lines harboring polyploid subpopulations (p-value = 0.00014, Unpaired t-test). A review of NOTCH1 mutations in T-ALL cell lines showed an association between NOTCH1 mutation status and chromosome number (p-value = 0.0066, Fisher Exact Test).ConclusionsHigh chromosome number associated with resistance to the inhibition of Aurora B and C suggests cells with a mechanism to bypass the high ploidy checkpoint are resistant to GSK1070916. High chromosome number, a hallmark trait of many late stage hematological malignancies, varies in prevalence among hematological malignancy subtypes. The high frequency and relative ease of measurement make high chromosome number a viable negative predictive marker for GSK1070916.
Cancer Research | 2016
Anastasia Wyce; Daniel J. Felitsky; Xiping Zhang; Jeanne J. Matteo; Susan Korenchuk; Lijoy K. Mathew; Melissa Musso; Sakina Khaku; Victoria Ortiz; Kathryn Keenan; Melissa Stern; Yan Degenhardt; Ramona Plant; Charles F. McHugh; Peter J. Tummino; Christopher Carpenter; Olena Barbash
BET (bromodomain and extra-terminal) family proteins are epigenetic readers that modulate expression genes involved in cell growth and oncogenesis. Selective small molecule BET inhibitors, such as the GSK I-BETs (I-BET762, I-BET151), abrogate binding of BET proteins to acetylated chromatin and inhibit transcription of BET target genes. We and others have previously demonstrated single agent activity for BET inhibitors in a number of pre-clinical solid and hematologic tumor models. Transcriptomics and mechanistic studies from several of these tumor types indicate that BET inhibitors influence numerous signaling pathways at the transcriptional level, including RAS/RAF/MEK signaling. Here we describe the synergistic effects of combining BET and MEK inhibitors in various solid and hematologic cancer models. We observe synergistic growth inhibition and apoptosis in a subset of cell lines representing multiple tumor types, as well as patient-derived xenograft models treated with the combination ex vivo. Additionally, combination of BET and MEK inhibitors results in improved tumor growth inhibition in cell line xenograft models compared to either single agent therapy. Further exploration of the combination in sensitive tumor types highlights multiple mechanisms potentially driving synergy, and suggests possible markers associated with sensitivity to the combination. Taken together, our data highlight the potential of BET/MEK inhibitor combinations to improve upon the efficacy observed for these agents as monotherapies in a wide variety of preclinical cancer models. All studies were conducted in accordance with the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals and were reviewed by the Institutional Animal Care and Use Committee either at GSK or by the ethical review process at the institution where the work was performed. Human biological samples were sourced ethically and their research use was in accord with the terms of the informed consents. Citation Format: Anastasia Wyce, Daniel J. Felitsky, Xi-Ping Zhang, Jeanne J. Matteo, Susan Korenchuk, Lijoy K. Mathew, Melissa Musso, Sakina Khaku, Victoria Ortiz, Kathryn Keenan, Melissa Stern, Yan Degenhardt, Ramona Plant, Charles F. McHugh, Peter J. Tummino, Christopher Carpenter, Olena Barbash. Broad activity for the combination of BET and MEK inhibitors across solid and hematologic cancers. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4709.